Structure-activity relationship and docking studies of thiazolidinedione-type compounds with monoamine oxidase B

被引：22

作者：

Carroll, Richard T. ^{[1
,2
]}

Dluzen, Dean E. ^{[1
,2
,3
,4
]}

Stinnett, Hilary ^{[1
,2
]}

Awale, Prabha S. ^{[1
,2
]}

Funk, Max O. ^{[5
]}

Geldenhuys, Werner J. ^{[1
,2
]}

机构：

[1] Northeastern Ohio Univ Coll Med & Pharm, Coll Med, Dept Pharmaceut Sci, Rootstown, OH 44272 USA

[2] Northeastern Ohio Univ Coll Med & Pharm, Coll Pharm, Dept Pharmaceut Sci, Rootstown, OH 44272 USA

[3] Northeastern Ohio Univ Coll Med & Pharm, Coll Med, Dept Anat & Neurobiol, Rootstown, OH 44272 USA

[4] Northeastern Ohio Univ Coll Med & Pharm, Coll Pharm, Dept Anat & Neurobiol, Rootstown, OH 44272 USA

[5] Univ Toledo, Dept Chem, Toledo, OH 43606 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2011年 / 21卷 / 16期

关键词：

Enzyme; Amplex-Red; Kynuramine; Pharmacophore; MPTP; GAMMA AGONIST PIOGLITAZONE; MOUSE MODEL; PARKINSONS-DISEASE; INHIBITORS;

D O I：

10.1016/j.bmcl.2011.06.060

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The neuroprotective activity of pioglitazone and rosiglitazone in the MPTP parkinsonian mouse prompted us to evaluate a set of thiazolidinedione (TZD) type compounds for monoamine oxidase A and B inhibition activity. These compounds were able to inhibit MAO-B over several log units of magnitude (82 nM to 600 mu M). Initial structure-activity relationship studies identified key areas to modify the aromatic substituted TZD compounds. Primarily, substitutions on the aromatic group and the TZD nitrogen were key areas where activity was enhanced within this group of compounds. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：4798 / 4803

页数：6

共 18 条

[11] Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists
Petzer, JP
Steyn, S
Castagnoli, KP
Chen, JF
Schwarzschild, MA
Van der Schyf, CJ
Castagnoli, N
[J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2003, 11 (07) : 1299 - 1310
[12] Inhibition of monoamine oxidase by indole and benzofuran derivatives
Prins, Louis H. A.
Petzer, Jacobus P.
Malan, Sarel F.
[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2010, 45 (10) : 4458 - 4466
[13] The PPARγ agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B
Quinn, L. P.
Crook, B.
Hows, M. E.
Vidgeon-Hart, M.
Chapman, H.
Upton, N.
Medhurst, A. D.
Virley, D. J.
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2008, 154 (01) : 226 - 233
[14] Synthesis and evaluation of β-carboline derivatives as potential monoamine oxidase inhibitors
Reniers, J.
Robert, S.
Frederick, R.
Masereel, B.
Vincent, S.
Wouters, J.
[J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (01) : 134 - 144
[15] PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease
Schintu, Nicoletta
Frau, Lucia
Ibba, Marcello
Caboni, Pierluigi
Garau, Arianna
Carboni, Ezio
Carta, Anna R.
[J]. EUROPEAN JOURNAL OF NEUROSCIENCE, 2009, 29 (05) : 954 - 963
[16] The therapeutic potential of monoamine oxidase inhibitors
Youdim, MBH
Edmondson, D
Tipton, KF
[J]. NATURE REVIEWS NEUROSCIENCE, 2006, 7 (04) : 295 - 309
[17] Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness
Youdim, MBH
Bakhle, YS
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2006, 147 : S287 - S296
[18] Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?
Youdim, Moussa B. H.
Geldenhuys, Werner J.
Van der Schyf, Cornelis J.
[J]. PARKINSONISM & RELATED DISORDERS, 2007, 13 : S281 - S291

← 1 2 →